RxDoctor Payments DataLook up a doctor →

John Riser, MD

Neurology · Birmingham, ALNPI 1134216088

Payments from drug & device makers

$229,008in general payments, 2019–2025

Across 997 payments — averaging $229.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$170K
  • AstraZeneca$13K
  • Sanofi$12K
  • MDD US Operations, LLC$9K
  • Tanabe Pharma America, Inc.$5K
  • Eli Lilly$4K
  • plus $15K from 51 others

What the payments were for

  • Consulting fees$15,22835%
  • Speaking & faculty fees$8,11518%
  • Travel & lodging$2,3005%
  • Food & beverage$18,25941%
  • Education$1490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi US Services Inc.19$170,385
AstraZeneca(2 entities)57$13,226
Sanofi18$12,344
MDD US Operations, LLC44$8,688
Tanabe Pharma America, Inc.55$5,124
Eli Lilly3$3,911
Biogen65$1,300
Amgen(2 entities)83$1,252
EMD Serono, Inc.46$1,219
Neurocrine Biosciences, Inc.41$998
TG Therapeutics, Inc.34$897
Bristol Myers Squibb34$817
UCB, Inc.32$801
AbbVie(2 entities)71$738
Mallinckrodt Hospital Products Inc.39$713
Pfizer39$684
Genentech USA, Inc.30$654
Argenx US, Inc.30$561
Novartis24$479
Lilly USA, LLC33$426
Acorda Therapeutics, Inc19$390
Johnson & Johnson(2 entities)11$297
Acadia Pharmaceuticals Inc17$291
Eisai Inc.8$189
Neurelis, Inc.13$182
Teva Pharmaceuticals USA, Inc.14$178
Assertio Therapeutics, Inc.11$172
Lundbeck LLC8$164
Adamas Pharmaceuticals, Inc.8$162
Biohaven Pharmaceuticals, Inc.7$160
EDW Pharma, Inc.3$157
Avanir Pharmaceuticals, Inc.13$151
CSL Behring6$140
Banner Life Sciences, LLC6$117
ANI Pharmaceuticals, Inc.3$92
Kyowa Kirin, Inc.4$78
E.r. Squibb & Sons, L.L.C.6$76
Arbor Pharmaceuticals, Inc.5$76
Harmony Biosciences LLC3$75
Upsher-smith Laboratories LLC4$69
Cycle Pharmaceuticals Inc4$64
Octapharma USA, Inc.2$48
Takeda Pharmaceuticals U.S.A., Inc.2$46
Boston Scientific2$45
Jazz Pharmaceuticals Inc.2$44
Axsome Therapeutics, Inc.2$42
Grifols USA, LLC2$39
Supernus Pharmaceuticals, Inc.2$35
Otsuka America Pharmaceutical, Inc.2$33
Catalyst Pharmaceuticals, Inc.2$31
Biohaven Pharmaceutical Holding Company Ltd.2$30
Zyla Life Sciences, Inc.2$25
Amylyx Pharmaceuticals, Inc.1$24
Sanofi-aventis U.S. LLC1$20
Mallinckrodt Enterprises LLC1$18
Kedrion Biopharma, Inc.1$17
Amneal Pharmaceuticals LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$229,008 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$306,941
Medicare patients
239
Services billed
6,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5045$658,156
Radicava OrsEdaravone25$375,390
Gamunex-CImmune Globul G/Gly/Iga Avg 4642$286,591
OctagamImmun Globg(Igg)/Malt/Iga Ov5011$129,837
NuplazidPimavanserin Tartrate11$52,909
Aimovig AutoinjectorErenumab-Aooe44$35,416
Emgality PenGalcanezumab-Gnlm50$34,407
InbrijaLevodopa17$32,995
QuliptaAtogepant19$20,206
UbrelvyUbrogepant11$11,183
LyricaPregabalin13$10,972
Lacosamide24$9,930
Carbidopa-LevodopaCarbidopa/Levodopa217$9,030
Pregabalin132$8,040
Pyridostigmine Bromide70$7,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$46$658,15645 claims
Grifols USA, LLCGamunex-C$39$286,59142 claims
PfizerOctagam, Lyrica$684$140,81024 claims
Acadia Pharmaceuticals IncNuplazid$291$52,90911 claims
Acorda Therapeutics, IncInbrija$390$32,99517 claims
AbbVieQulipta, Ubrelvy$738$31,38930 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$13$8,57282 claims
Upsher-smith Laboratories LLCTopiramate$69$36761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 neurology providers in Alabama.

Other neurology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →